The evidence for a regulatory role in the pathogenesis of dystrophic cardiomyopathy provides further incentive to the assessment of the clinical relevance of PTX3 measurement in prognostic value and in guiding therapy for cardiomyopathy of DMD. The gene discussed is PTX3; the disease is Duchenne muscular dystrophy.